CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.54
1.82%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Exicure Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.55
Open* 0.55
1-Year Change* -47.62%
Day's Range* 0.54 - 0.56
52 wk Range 0.36-1.58
Average Volume (10 days) 1.65M
Average Volume (3 months) 17.24M
Market Cap 5.24M
P/E Ratio 0.47
Shares Outstanding 8.65M
Revenue 23.79M
EPS 1.28
Dividend (Yield %) N/A
Beta 1.18
Next Earnings Date Jan 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 0.54 -0.01 -1.82% 0.55 0.56 0.54
Apr 18, 2024 0.55 -0.03 -5.17% 0.58 0.58 0.55
Apr 17, 2024 0.56 -0.02 -3.45% 0.58 0.58 0.56
Apr 16, 2024 0.56 0.01 1.82% 0.55 0.66 0.55
Apr 15, 2024 0.58 0.01 1.75% 0.57 0.58 0.56
Apr 12, 2024 0.56 -0.01 -1.75% 0.57 0.58 0.55
Apr 11, 2024 0.56 -0.01 -1.75% 0.57 0.58 0.56
Apr 10, 2024 0.57 0.01 1.79% 0.56 0.58 0.56
Apr 9, 2024 0.57 0.01 1.79% 0.56 0.58 0.56
Apr 8, 2024 0.55 0.02 3.77% 0.53 0.57 0.52
Apr 5, 2024 0.53 0.01 1.92% 0.52 0.54 0.52
Apr 4, 2024 0.52 -0.01 -1.89% 0.53 0.54 0.48
Apr 3, 2024 0.54 -0.04 -6.90% 0.58 0.58 0.54
Apr 2, 2024 0.57 -0.01 -1.72% 0.58 0.58 0.54
Apr 1, 2024 0.58 0.00 0.00% 0.58 0.58 0.55
Mar 28, 2024 0.57 0.00 0.00% 0.57 0.57 0.56
Mar 27, 2024 0.58 -0.01 -1.69% 0.59 0.60 0.58
Mar 26, 2024 0.58 0.00 0.00% 0.58 0.58 0.58
Mar 25, 2024 0.59 -0.02 -3.28% 0.61 0.61 0.58
Mar 22, 2024 0.59 -0.01 -1.67% 0.60 0.60 0.59

Exicure, Inc. Events

Time (UTC) Country Event
Friday, July 12, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Exicure Inc Earnings Release
Q1 2024 Exicure Inc Earnings Release

Forecast

-

Previous

-
Friday, August 9, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Exicure Inc Earnings Release
Q2 2024 Exicure Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 28.826 -0.483 16.613 1.296 0.118
Revenue 28.826 -0.483 16.613 1.296 0.118
Total Operating Expense 30.657 62.066 42.049 27.913 21.937
Selling/General/Admin. Expenses, Total 10.89 13.087 9.955 8.573 7.818
Research & Development 19.767 48.979 32.094 19.34 14.119
Operating Income -1.831 -62.549 -25.436 -26.617 -21.819
Interest Income (Expense), Net Non-Operating -0.502 -1.542 0.446 -0.065 -0.672
Other, Net -0.04 -0.011 0.322 0.379 0.078
Net Income Before Taxes -2.373 -64.102 -24.668 -26.303 -22.413
Net Income After Taxes -2.582 -64.102 -24.668 -26.303 -22.413
Net Income Before Extra. Items -2.582 -64.102 -24.668 -26.303 -22.413
Net Income -2.582 -64.102 -24.668 -26.303 -22.413
Income Available to Common Excl. Extra. Items -2.582 -64.102 -24.668 -26.303 -22.413
Income Available to Common Incl. Extra. Items -2.582 -64.102 -24.668 -26.303 -22.413
Diluted Net Income -2.582 -64.102 -24.668 -26.303 -22.413
Diluted Weighted Average Shares 4.61947 2.95391 2.9065 1.9222 1.37284
Diluted EPS Excluding Extraordinary Items -0.55894 -21.7007 -8.4872 -13.6838 -16.3261
Diluted Normalized EPS -0.55655 -21.7007 -8.4872 -13.6838 -16.3261
Total Extraordinary Items 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 21.774 2.016 2.471
Revenue 0 0 21.774 2.016 2.471
Total Operating Expense 5.642 4.539 3.18 7.221 9.954
Selling/General/Admin. Expenses, Total 4.721 2.558 2.107 2.416 3.205
Research & Development 0.921 1.981 1.073 4.805 6.749
Operating Income -5.642 -4.539 18.594 -5.205 -7.483
Interest Income (Expense), Net Non-Operating 0.028 0.028 0.027 0.045 0.017
Other, Net -0.106 0.104 -0.016 0 -0.004
Net Income Before Taxes -5.764 -4.407 18.605 -5.16 -7.47
Net Income After Taxes -5.764 -4.407 18.396 -5.16 -7.47
Net Income Before Extra. Items -5.764 -4.407 18.396 -5.16 -7.47
Net Income -5.764 -4.407 18.396 -5.16 -7.47
Income Available to Common Excl. Extra. Items -5.764 -4.407 18.396 -5.16 -7.47
Income Available to Common Incl. Extra. Items -5.764 -4.407 18.396 -5.16 -7.47
Diluted Net Income -5.764 -4.407 18.396 -5.16 -7.47
Diluted Weighted Average Shares 8.43239 6.28895 4.969 4.96334 4.50398
Diluted EPS Excluding Extraordinary Items -0.68355 -0.70075 3.70215 -1.03962 -1.65853
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.6666 -0.71649 3.70215 -1.03962 -1.65853
Gain (Loss) on Sale of Assets -0.044
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 10.051 43.666 86.322 112.776 27.663
Cash and Short Term Investments 8.577 39.141 82.08 110.786 26.268
Cash & Equivalents 8.577 34.644 33.262 48.46 26.268
Total Receivables, Net 0 0.011 0.271 0.013
Accounts Receivable - Trade, Net 0 0.011 0.035 0.003
Prepaid Expenses 0.621 3.247 4.231 1.014 1.382
Total Assets 23.328 64.868 100.444 115.263 28.756
Property/Plant/Equipment, Total - Net 9.787 11.877 12.729 2.455 1.061
Property/Plant/Equipment, Total - Gross 13.437 14.544 14.469 3.772 2.25
Accumulated Depreciation, Total -3.65 -2.667 -1.74 -1.317 -1.189
Other Long Term Assets, Total 3.49 9.325 1.393 0.032 0.032
Total Current Liabilities 1.639 34.067 13.734 31.087 2.043
Accounts Payable 0.361 3.413 1.866 1.814 0.5
Accrued Expenses 1.278 6.464 3.525 2.435 1.543
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 6.873 0 4.965
Other Current Liabilities, Total 0 17.317 8.343 21.873 0
Total Liabilities 8.406 53.636 38.938 34.516 7.804
Total Long Term Debt 0 0 16.589 0 4.925
Long Term Debt 0 16.589 0 4.925
Other Liabilities, Total 6.767 19.569 8.615 3.429 0.836
Total Equity 14.922 11.232 61.506 80.747 20.952
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.0005 0.011 0.009 0.009 0.004
Additional Paid-In Capital 187.571 181.29 167.379 162.062 75.942
Retained Earnings (Accumulated Deficit) -172.649 -170.067 -105.965 -81.297 -54.994
Total Liabilities & Shareholders’ Equity 23.328 64.868 100.444 115.263 28.756
Total Common Shares Outstanding 4.9659 3.62574 2.92142 2.86869 1.47845
Short Term Investments 0 4.497 48.818 62.326
Other Current Assets, Total 0.853 1.278 0.705
Other Equity, Total -0.0005 -0.002 0.083 -0.027
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 3.664 11.277 10.051 17.198 24.721
Cash and Short Term Investments 2.335 9.96 8.577 15.646 22.195
Cash & Equivalents 2.335 9.96 8.577 15.646 21.198
Short Term Investments 0 0 0.997
Total Receivables, Net
Accounts Receivable - Trade, Net
Prepaid Expenses 0.628 0.801 0.621 0.538 1.327
Other Current Assets, Total 0.701 0.516 0.853 1.014 1.199
Total Assets 17.555 23.943 23.328 28.942 36.955
Property/Plant/Equipment, Total - Net 8.689 9.356 9.787 10.467 10.934
Property/Plant/Equipment, Total - Gross 12.251 13.102 13.437 14.009 14.187
Accumulated Depreciation, Total -3.562 -3.746 -3.65 -3.542 -3.253
Other Long Term Assets, Total 3.202 3.31 3.49 1.277 1.3
Total Current Liabilities 1.431 2.729 1.639 25.71 19.656
Accounts Payable 0.343 0.452 0.361 0.92 1.593
Accrued Expenses 1.088 1.477 1.278 3.016 3.308
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.8 0 21.774 14.755
Total Liabilities 7.85 9.324 8.406 32.645 35.792
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 6.419 6.595 6.767 6.935 16.136
Total Equity 9.705 14.619 14.922 -3.703 1.163
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.001 0.001 0.0005 0.0005 0.0005
Additional Paid-In Capital 192.524 191.674 187.571 187.343 187.053
Retained Earnings (Accumulated Deficit) -182.82 -177.056 -172.649 -191.045 -185.885
Other Equity, Total -0.0005 -0.0015 -0.0055
Total Liabilities & Shareholders’ Equity 17.555 23.943 23.328 28.942 36.955
Total Common Shares Outstanding 8.64831 8.37146 4.9659 4.96431 4.96223
Current Port. of LT Debt/Capital Leases 0 0 0
Long Term Investments 2
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -2.582 -64.102 -24.668 -26.303 -22.413
Cash From Operating Activities -35.658 -34.819 -39.27 1.317 -19.487
Cash From Operating Activities 1.163 1.123 0.766 0.392 0.358
Non-Cash Items 2.537 4.048 2.896 1.981 2.179
Changes in Working Capital -36.776 24.112 -18.264 25.247 0.389
Cash From Investing Activities 4.696 43.085 10.142 -63.432 -0.094
Capital Expenditures -0.01 -0.968 -3.171 -1.082 -0.094
Cash From Financing Activities -3.105 1.116 15.13 84.307 20.085
Financing Cash Flow Items -0.664 -1.125 -0.711 -6.518 -1.957
Issuance (Retirement) of Stock, Net 5.059 12.241 3.34 90.825 22.042
Issuance (Retirement) of Debt, Net -7.5 -10 12.501 0
Net Change in Cash -34.067 9.382 -13.998 22.192 0.504
Other Investing Cash Flow Items, Total 4.706 44.053 13.313 -62.35
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Net income/Starting Line -2.582 -20.978 -15.818 -8.348 -64.102
Cash From Operating Activities -35.658 -28.382 -21.834 -12.756 -34.819
Cash From Operating Activities 1.163 0.882 0.593 0.302 1.123
Non-Cash Items 2.537 2.155 1.683 1.006 4.048
Changes in Working Capital -36.776 -10.441 -8.292 -5.716 24.112
Cash From Investing Activities 4.696 4.489 3.491 1.995 43.085
Capital Expenditures -0.01 -0.01 -0.01 -0.006 -0.968
Other Investing Cash Flow Items, Total 4.706 4.499 3.501 2.001 44.053
Cash From Financing Activities -3.105 -3.105 -3.103 -7.993 1.116
Financing Cash Flow Items -0.664 -0.664 -0.662 -0.507 -1.125
Issuance (Retirement) of Stock, Net 5.059 5.059 5.059 0.014 12.241
Issuance (Retirement) of Debt, Net -7.5 -7.5 -7.5 -7.5 -10
Net Change in Cash -34.067 -26.998 -21.446 -18.754 9.382

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Exicure, Inc. Company profile

About Exicure Inc

Exicure, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The Company develops XCUR-FXN, which is a spherical nucleic acid (SNA) -based therapeutic candidate for the treatment of Friedreich’s ataxia (FA). XCUR-FXN through its SNA technology incorporates more than one active oligonucleotides in a single SNA molecule. The Company’s therapeutic candidate cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9) agonist designed for immuno-oncology applications utilizing its SNA technology. AST-008 is in a Phase I b/II clinical trial in patients with advanced solid tumors. TLR9 agonists binds to and activate TLR9.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Exicure Inc revenues decreased from $16.5M to -$2.6M. Net loss increased from $12M to $50.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expense - Balan increase of 69% to $36.5M (expense), General and administrative expense - Bal increase of 25% to $7.8M (expense).

Industry: Bio Therapeutic Drugs

2430 N. Halsted St.
CHICAGO
ILLINOIS 60614
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

64,804.90 Price
-0.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

ETH/USD

3,153.90 Price
-0.150% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading